These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

189 related articles for article (PubMed ID: 35416344)

  • 1. Serum IL-22 binding protein as a marker for atopic dermatitis activity and response to dupilumab treatment.
    Varandas C; Pereira-Santos MC; Neto M; Sousa AE; Lopes A; Silva SL
    Clin Exp Allergy; 2022 Jun; 52(6):820-823. PubMed ID: 35416344
    [No Abstract]   [Full Text] [Related]  

  • 2. EASI p-EASI: Predicting disease severity in atopic dermatitis patients treated with dupilumab using a combination of serum biomarkers.
    Bakker DS; Ariens LFM; Giovannone B; Hijnen D; Delemarre EM; Knol E; Nierkens S; de Bruin-Weller MS; Thijs JL; Drylewicz J
    Allergy; 2020 Dec; 75(12):3287-3289. PubMed ID: 33305359
    [No Abstract]   [Full Text] [Related]  

  • 3. Serum biomarker analysis to identify subtypes of atopic dermatitis in China and to help with predicting the effectiveness of treatment with dupilumab.
    Br J Dermatol; 2023 Apr; 188(5):e37. PubMed ID: 37078765
    [No Abstract]   [Full Text] [Related]  

  • 4. Biomarkers in tear fluid of dupilumab-treated moderate-to-severe atopic dermatitis patients.
    Achten R; Thijs J; van Luijk C; Knol E; Delemarre E; de Graaf M; Bakker D; de Boer J; van Wijk F; de Bruin-Weller M
    Clin Exp Allergy; 2023 Feb; 53(2):239-243. PubMed ID: 36550628
    [No Abstract]   [Full Text] [Related]  

  • 5. Dupilumab for the Treatment of Atopic Dermatitis.
    Ferreira S; Torres T
    Actas Dermosifiliogr (Engl Ed); 2018 Apr; 109(3):230-240. PubMed ID: 29422431
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Novel Therapeutic Approaches and Targets for the Treatment of Atopic Dermatitis.
    Pescitelli L; Rosi E; Ricceri F; Pimpinelli N; Prignano F
    Curr Pharm Biotechnol; 2021; 22(1):73-84. PubMed ID: 32525769
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Psoriasis in dupilumab-treated atopic dermatitis].
    Senner S; Eicher L; Aszodi N; Prinz JC; French LE; Wollenberg A
    Hautarzt; 2020 May; 71(5):383-386. PubMed ID: 32179945
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Dupilumab: A review of its use in the treatment of atopic dermatitis.
    Gooderham MJ; Hong HC; Eshtiaghi P; Papp KA
    J Am Acad Dermatol; 2018 Mar; 78(3 Suppl 1):S28-S36. PubMed ID: 29471919
    [TBL] [Abstract][Full Text] [Related]  

  • 9. IL-13 antagonists in the treatment of atopic dermatitis.
    Tubau C; Puig L
    Immunotherapy; 2021 Mar; 13(4):327-344. PubMed ID: 33430628
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Reported Pregnancy Outcomes in Women With Severe Atopic Dermatitis Treated With Dupilumab: A Systematic Review.
    Akuffo-Addo E; Nicholas MN; Lansang P
    J Cutan Med Surg; 2023; 27(2):177-178. PubMed ID: 36721993
    [No Abstract]   [Full Text] [Related]  

  • 11. Association study of transition of laboratory marker levels and transition of disease activity of atopic dermatitis patients treated with dupilumab.
    Mizuno M; Horiguchi G; Teramukai S; Ichiyama S; Ito M; Hoashi T; Kanda N; Saeki H
    Australas J Dermatol; 2021 Nov; 62(4):e504-e509. PubMed ID: 34523731
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Dose reduction of dupilumab in atopic patients with controlled atopic dermatitis: A safe and effective practice?
    Mastorino L; Gelato F; Richiardi I; Cavaliere G; Quaglino P; Ortoncelli M; Ribero S
    J Eur Acad Dermatol Venereol; 2023 May; 37(5):e691-e692. PubMed ID: 36688263
    [No Abstract]   [Full Text] [Related]  

  • 13. Successful dose reduction of dupilumab in atopic dermatitis.
    Ardern-Jones MR; Buchanan EE; Njungu S; O'Driscoll D
    Br J Dermatol; 2023 Apr; 188(5):678-679. PubMed ID: 36662536
    [No Abstract]   [Full Text] [Related]  

  • 14. Dupilumab provides rapid improvement for morphologic variants of paediatric atopic dermatitis: A case series.
    Kim JW; Kim M; Ahn GS; Na JI
    Indian J Dermatol Venereol Leprol; 2022; 88(6):834-839. PubMed ID: 36331828
    [No Abstract]   [Full Text] [Related]  

  • 15. Purpuric Drug Eruption in a Patient with Atopic Dermatitis Treated with Dupilumab.
    Wang M; Zheng Q; Tang S; Shen F; Jiang W
    Acta Derm Venereol; 2022 Jun; 102():adv00744. PubMed ID: 35670327
    [No Abstract]   [Full Text] [Related]  

  • 16. Prediction of response to dupilumab treatment.
    Hijnen D; Olydam J
    Br J Dermatol; 2023 May; 188(6):e41. PubMed ID: 37167296
    [No Abstract]   [Full Text] [Related]  

  • 17. Dupilumab therapy rapidly improved alopecia areata associated with trichotillomania in an atopic dermatitis patient.
    Ushida M; Ohshita A; Arakawa Y; Kanehisa F; Katoh N; Asai J
    Allergol Int; 2020 Jul; 69(3):480-482. PubMed ID: 32234288
    [No Abstract]   [Full Text] [Related]  

  • 18. Dupilumab use in atopic dermatitis and beyond in skin diseases.
    Fourzali K; Golpanian RS; Yosipovitch G
    Immunotherapy; 2020 Dec; 12(17):1221-1235. PubMed ID: 32892674
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Discordant lymphomas of classic Hodgkin lymphoma and peripheral T-cell lymphoma following dupilumab treatment for atopic dermatitis.
    Nakazaki K; Yoshida M; Masamoto Y; Shinozaki-Ushiku A; Ikemura M; Hisamoto T; Yasunaga M; Sato S; Kurokawa M
    Int J Hematol; 2022 Sep; 116(3):446-452. PubMed ID: 35355217
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Dupilumab is very effective in a large cohort of difficult-to-treat adult atopic dermatitis patients: First clinical and biomarker results from the BioDay registry.
    Ariëns LFM; van der Schaft J; Bakker DS; Balak D; Romeijn MLE; Kouwenhoven T; Kamsteeg M; Giovannone B; Drylewicz J; van Amerongen CCA; Delemarre EM; Knol EF; van Wijk F; Nierkens S; Thijs JL; Schuttelaar MLA; de Bruin-Weller MS
    Allergy; 2020 Jan; 75(1):116-126. PubMed ID: 31593343
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.